Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
NCT05707910Phase 1Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBV immunological agent in cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: Adverse events at 12 months, Objective response rate at 12 months and 2 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
EBV immunological agent
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05707910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707910.